Even better, according to the published research findings, these new psychedelic solutions are producing “large, rapid, and sustained antidepressant effects in patients with major depressive disorder.”
Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF), is on the cutting edge of this new era of mental health treatment. With a visionary leadership consisting of industry veterans and a strong research team of innovative scientists, Cybin – a “tiny” biotech company – has massive levels of output…
To accelerate the growth of the company, Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) is deploying a “three pillar” strategy…
1 (https://www.who.int/whr/2001/media_centre/press_release/e n/) & (https://www.mirror-mirror.org/eating-disordersstatistics. htm) & (https://drugfree.org/learn/drug-and-alcoholnews/ researchers-release-first-report-worldwide-addictionstatistics/)
4 Kyzar, E. J.; Nichols, C. D.; Gainetdinov, R. R.; Nichols, D. E.; Kalueff, A. V., Psychedelic Drugs in Biomedicine. Trends Pharmacol Sci 2017, 38 (11), 992-1005.